These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

525 related articles for article (PubMed ID: 34812991)

  • 21. Triple-negative breast cancer therapeutic resistance: Where is the Achilles' heel?
    Bai X; Ni J; Beretov J; Graham P; Li Y
    Cancer Lett; 2021 Jan; 497():100-111. PubMed ID: 33069769
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A review of nanotechnology-based approaches for breast cancer and triple-negative breast cancer.
    Jain V; Kumar H; Anod HV; Chand P; Gupta NV; Dey S; Kesharwani SS
    J Control Release; 2020 Oct; 326():628-647. PubMed ID: 32653502
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Androgen Receptor Biology in Triple Negative Breast Cancer: a Case for Classification as AR+ or Quadruple Negative Disease.
    Barton VN; D'Amato NC; Gordon MA; Christenson JL; Elias A; Richer JK
    Horm Cancer; 2015 Dec; 6(5-6):206-13. PubMed ID: 26201402
    [TBL] [Abstract][Full Text] [Related]  

  • 24. miR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer.
    Li HY; Liang JL; Kuo YL; Lee HH; Calkins MJ; Chang HT; Lin FC; Chen YC; Hsu TI; Hsiao M; Ger LP; Lu PJ
    Breast Cancer Res; 2017 Dec; 19(1):133. PubMed ID: 29258605
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous disease.
    Mehlich D; Marusiak AA
    Cancer Lett; 2022 Oct; 547():215775. PubMed ID: 35667515
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer.
    He J; McLaughlin RP; van der Noord V; Foekens JA; Martens JWM; van Westen G; Zhang Y; van de Water B
    Breast Cancer Res Treat; 2019 Nov; 178(2):263-274. PubMed ID: 31388935
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells.
    Koike Y; Ohta Y; Saitoh W; Yamashita T; Kanomata N; Moriya T; Kurebayashi J
    Breast Cancer; 2017 Sep; 24(5):683-693. PubMed ID: 28144905
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.
    Costa RLB; Han HS; Gradishar WJ
    Breast Cancer Res Treat; 2018 Jun; 169(3):397-406. PubMed ID: 29417298
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of secreted frizzled receptor protein 1 (SFRP1) on neoadjuvant chemotherapy in triple negative breast cancer does not rely on WNT signaling.
    Bernemann C; Hülsewig C; Ruckert C; Schäfer S; Blümel L; Hempel G; Götte M; Greve B; Barth PJ; Kiesel L; Liedtke C
    Mol Cancer; 2014 Jul; 13():174. PubMed ID: 25033833
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PKCλ/ι signaling promotes triple-negative breast cancer growth and metastasis.
    Paul A; Gunewardena S; Stecklein SR; Saha B; Parelkar N; Danley M; Rajendran G; Home P; Ray S; Jokar I; Vielhauer GA; Jensen RA; Tawfik O; Paul S
    Cell Death Differ; 2014 Sep; 21(9):1469-81. PubMed ID: 24786829
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treating triple negative breast cancer cells with erlotinib plus a select antioxidant overcomes drug resistance by targeting cancer cell heterogeneity.
    Bao B; Mitrea C; Wijesinghe P; Marchetti L; Girsch E; Farr RL; Boerner JL; Mohammad R; Dyson G; Terlecky SR; Bollig-Fischer A
    Sci Rep; 2017 Mar; 7():44125. PubMed ID: 28281569
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic targets of triple-negative breast cancer: a review.
    Jamdade VS; Sethi N; Mundhe NA; Kumar P; Lahkar M; Sinha N
    Br J Pharmacol; 2015 Sep; 172(17):4228-37. PubMed ID: 26040571
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hypoxia-induced tRNA-derived fragments, novel regulatory factor for doxorubicin resistance in triple-negative breast cancer.
    Cui Y; Huang Y; Wu X; Zheng M; Xia Y; Fu Z; Ge H; Wang S; Xie H
    J Cell Physiol; 2019 Jun; 234(6):8740-8751. PubMed ID: 30362543
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor microenvironment: Challenges and opportunities in targeting metastasis of triple negative breast cancer.
    Deepak KGK; Vempati R; Nagaraju GP; Dasari VR; S N; Rao DN; Malla RR
    Pharmacol Res; 2020 Mar; 153():104683. PubMed ID: 32050092
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Down-regulating GRP78 reverses pirarubicin resistance of triple negative breast cancer by miR-495-3p mimics and involves the p-AKT/mTOR pathway.
    Liu M; Yang J; Lv W; Wang S; Du T; Zhang K; Wu Y; Feng X
    Biosci Rep; 2022 Jan; 42(1):. PubMed ID: 34935899
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Suppressive role exerted by microRNA-29b-1-5p in triple negative breast cancer through SPIN1 regulation.
    Drago-Ferrante R; Pentimalli F; Carlisi D; De Blasio A; Saliba C; Baldacchino S; Degaetano J; Debono J; Caruana-Dingli G; Grech G; Scerri C; Tesoriere G; Giordano A; Vento R; Di Fiore R
    Oncotarget; 2017 Apr; 8(17):28939-28958. PubMed ID: 28423652
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of USP2 eliminates cancer stem cells and enhances TNBC responsiveness to chemotherapy.
    He J; Lee HJ; Saha S; Ruan D; Guo H; Chan CH
    Cell Death Dis; 2019 Mar; 10(4):285. PubMed ID: 30918246
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent treatment progress of triple negative breast cancer.
    Chang-Qing Y; Jie L; Shi-Qi Z; Kun Z; Zi-Qian G; Ran X; Hui-Meng L; Ren-Bin Z; Gang Z; Da-Chuan Y; Chen-Yan Z
    Prog Biophys Mol Biol; 2020 Mar; 151():40-53. PubMed ID: 31761352
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The autophagy inhibitor chloroquine targets cancer stem cells in triple negative breast cancer by inducing mitochondrial damage and impairing DNA break repair.
    Liang DH; Choi DS; Ensor JE; Kaipparettu BA; Bass BL; Chang JC
    Cancer Lett; 2016 Jul; 376(2):249-58. PubMed ID: 27060208
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Interleukin-22 promotes triple negative breast cancer cells migration and paclitaxel resistance through JAK-STAT3/MAPKs/AKT signaling pathways.
    Wang S; Yao Y; Yao M; Fu P; Wang W
    Biochem Biophys Res Commun; 2018 Sep; 503(3):1605-1609. PubMed ID: 30072097
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 27.